Status:
COMPLETED
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Lead Sponsor:
Samsung Medical Center
Conditions:
Inflammatory Lung Diseases
Hemoptysis
Eligibility:
All Genders
20-90 years
Brief Summary
Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been ...
Eligibility Criteria
Inclusion
- patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung
Exclusion
- patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01171768
Start Date
June 1 2008
End Date
December 1 2010
Last Update
July 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea